Clinical Research Directory

Inclusion Criteria: * Both sexes; * Age ≥18 years; * Signed informed consent form for participation in the study; * Presence of at least one clinical symptom possibly related to chronic venous disease (such as heaviness and/or swelling and/or pain in the lower limbs, nighttime cramps, tired/heavy legs, itching, burning and/or warmth, tingling, or restlessness in the lower limbs); * Willingness to participate in the study and to comply with the study procedures, as confirmed by signing the written informed consent. Exclusion Criteria: * Pregnancy or current breastfeeding; * Women of childbearing potential who are not using adequate birth control methods (either hormonal contraception in the form of contraceptive pills, or barrier birth control methods used in combination with a spermicidal product such as foam, gel, or film). \[For the entire duration of the study, women of childbearing potential-defined as those who are less than one year post-menopause or who have not undergone hysterectomy or tubal ligation-must use an effective method of contraception, in accordance with Note 3 of the ICH M3 Guideline. A contraceptive method is considered highly effective if it results in a failure rate of less than 1% per year. Effective contraceptive methods include: hormonal contraceptives containing estrogens and progestins (oral, intravaginal, transdermal) that inhibit ovulation; hormonal contraceptives containing progestins only (oral, injectable, implantable); intrauterine devices (IUDs); hormone-releasing intrauterine systems (IUS); partner vasectomy; sexual abstinence\]; * Individuals with chronic venous insufficiency classified as CEAP stages C3-C6 (see Annex 1); * Individuals with a positive pitting edema sign detected at Visit 1 after signing the informed consent; * Patients with documented deep vein thrombosis within the last 6 months; * Current or recent (within the last 4 weeks) use of venoactive and/or anti-edematous products; * Individuals scheduled for surgical procedures within 3 months of enrollment; * Subjects with a history of heart failure (NYHA Class III-IV), chronic kidney disease, and/or severe hepatic insufficiency; * Ongoing oncological or immunosuppressive diseases; * Celiac disease; * Drug and/or alcohol abuse; * Neurological or psychiatric disorders that may impair the validity of informed consent and/or compromise adherence to the study procedures; * Known allergy, hypersensitivity, or intolerance to any component of the investigational dietary supplement; * Any medical or non-medical condition that, in the opinion of the Investigator, could interfere with the study or make participation unsafe; * Subjects currently enrolled in other clinical trials, or who have received another investigational product within 30 days prior to study start; * Individuals who have not signed the informed consent form.